News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Peer Review
December 21, 2023
Endpoints News
Read Now
Press Release
Peer Review
December 21, 2023
Endpoints News
Read Now
News
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
December 20, 2023
Read Now
Press Release
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
December 20, 2023
Read Now
News
FDA approves CRISPR–Cas9 therapy for sickle cell disease
December 8, 2023
ASBMB Today
Read Now
Press Release
FDA approves CRISPR–Cas9 therapy for sickle cell disease
December 8, 2023
ASBMB Today
Read Now
News
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now
Press Release
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now